RESUMEN
The appropriateness of house dust mite specific immunotherapy in patients allergic to shrimps still remains unclear We present a clinical case as an immunological model for the strong sensitization to tropomyosin with symptoms of anaphylaxis due to shrimps and coexisting asthma due to house dust mite. The improvement in respiratory symptoms for house dust mite and in the food challenge for shrimps during mite immunotherapy with a known and high dosage of tropomyosin suggests the hypothesis that efficacy of mite immunotherapy in food allergy to tropomyosin may be dose dependent.
Asunto(s)
Antígenos Dermatofagoides/inmunología , Asma/tratamiento farmacológico , Desensibilización Inmunológica , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Tropomiosina/inmunología , Administración Sublingual , Adolescente , Animales , Antígenos Dermatofagoides/metabolismo , Asma/complicaciones , Asma/inmunología , Reacciones Cruzadas/fisiología , Hipersensibilidad a los Alimentos/complicaciones , Hipersensibilidad a los Alimentos/inmunología , Humanos , Masculino , Penaeidae/inmunología , Penaeidae/metabolismo , Pyroglyphidae/inmunología , Pyroglyphidae/metabolismo , Mariscos/efectos adversos , Resultado del Tratamiento , Tropomiosina/metabolismoRESUMEN
BACKGROUND: No studies have directly compared the effects of immunotherapy and antileukotrienes due to the long time required to appreciate the clinical effects of immunotherapy. We compared the effect of montelukast (MK) and SLIT added to standard therapy in moderate asthma over 5 years. METHODS: Open randomized controlled trial. Patients with moderate asthma (and rhinitis) solely due to birch pollen were randomized to receive either MK (10 mg/d) or birch sublingual immunotherapy (SLIT) in the pollen seasons, in addition to formoterol/fluticasone. All the patients also received salbutamol and cetirizine as rescue medications. Asthma and rhinitis symptoms were recorded on diary cards from February to May at baseline and after 3 and 5 years of study. In-season nasal eosinophils and bronchial hyperresponsiveness were also evaluated. RESULTS: Thirty-three adult patients were enrolled and 29 completed the study. The groups were homogeneous at baseline. Bronchial and nasal symptom scores were lower at 3 and 5 years compared to baseline in the SLIT group. Bronchial hyperresponsiveness and bronchodilator use decreased significantly in both groups at 5 years, but only in the SLIT group at 3 years. In the SLIT group there was a significant decrease in nasal eosinophils compared to baseline and to the MK group. CONCLUSION: In patients with birch pollen-induced moderate asthma and rhinitis, the addition of SLIT provides a greater clinical benefit than that of MK.
Asunto(s)
Acetatos/administración & dosificación , Asma/terapia , Desensibilización Inmunológica , Antagonistas de Leucotrieno/administración & dosificación , Quinolinas/administración & dosificación , Rinitis Alérgica Estacional/terapia , Acetatos/efectos adversos , Administración Sublingual , Adolescente , Adulto , Anciano , Antígenos de Plantas/administración & dosificación , Antígenos de Plantas/efectos adversos , Antígenos de Plantas/inmunología , Asma/etiología , Asma/inmunología , Asma/fisiopatología , Betula/inmunología , Recuento de Células , Ciclopropanos , Progresión de la Enfermedad , Eosinofilia , Femenino , Estudios de Seguimiento , Humanos , Antagonistas de Leucotrieno/efectos adversos , Masculino , Persona de Mediana Edad , Obstrucción Nasal , Quinolinas/efectos adversos , Rinitis Alérgica Estacional/complicaciones , Rinitis Alérgica Estacional/inmunología , Rinitis Alérgica Estacional/fisiopatología , SulfurosRESUMEN
The American Polistes species venom mixture--that of P. annularis, P. fuscatus, P. metricus and P. exclamans--was the only commercially available mixture for diagnosis and therapy until 1996. However, these species of Polistes are not present in Europe, where P. dominulus and P. gallicus and to a lesser extent P. nimphus are widespread. The aim of this study was to assess the allergenic differences among the commercial American mix, P. dominulus and P. gallicus venom in European patients and therefore to verify if this mixture is suitable for diagnosis in these patients. We carried out skin tests, radioallergosorbent tests (RAST) and RAST inhibition in Italian patients with adverse reactions to Polistes stings. RAST inhibition results demonstrated that cross-reactivity between the American and European species is only partial and that P. dominulus and P. gallicus venoms have exclusive allergens. Skin tests and direct RAST confirmed these results and also showed that European Polistes venom is more suitable than the American mix in Italian patients. Moreover, we found a high rate of cross-reactivity between P. dominulus and P. gallicus. To conclude, P. dominulus and/or P. gallicus venoms are necessary for diagnosis and therefore in the therapy of European patients.
Asunto(s)
Alérgenos/inmunología , Hipersensibilidad/inmunología , Mordeduras y Picaduras de Insectos/inmunología , Venenos de Avispas/inmunología , Adolescente , Adulto , Anciano , Animales , Europa (Continente) , Femenino , Humanos , Hipersensibilidad/diagnóstico , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Masculino , Persona de Mediana Edad , Prueba de Radioalergoadsorción , Pruebas Cutáneas , Estados Unidos , AvispasRESUMEN
BACKGROUND: Some aspects of allergic progression still need to be addressed. To prevent the onset of the progression is not, at present, a very realistic aim, although therapeutic instruments are available to delay and, if possible, to stop it. We attempted to clarify these points in an observational open controlled three-parallel group study in a real-life setting. METHODS: 3838 patients with respiratory allergy due to house dust mite have been enrolled in this observational study. 2200 patients with rhinitis and/or intermittent or mild persistent asthma, poorly responsive to standard pharmacological therapy (SPT) were treated for three years with SPT associated or not with specific immunotherapy (SIT). Symptom medication scores, pulmonary function test (PFT) and methacholine (MCh) challenge were performed at the beginning and at the end of the study. 1638 pure rhinitics, responsive to SPT, enrolled as a control group, used self-medication (SM) on demand to assess the incidence of asthma in non-treated patients with standard therapeutic protocols. RESULTS: 694 patients have been treated with SPT+SIT, 1506 with SPT and 1638 with SM. Co-morbidity rhinitis-asthma incidence was higher in the SM group (an overall 69.27% including asthma and bronchial hyperreactivity). Persistent rhinitis proved more often to be associated with asthma than intermittent rhinitis. Likewise, the moderate-severe forms compared to the mild ones. The addition of SIT to SPT reduced the allergic progression in all patients. CONCLUSIONS: In everyday clinical practice too, SIT proves its efficacy in the treatment of allergic march. Patients with moderate-severe persistent rhinitis appear as the ideal candidates for this therapy.
Asunto(s)
Asma/epidemiología , Pyroglyphidae/inmunología , Hipersensibilidad Respiratoria/epidemiología , Rinitis Alérgica Perenne/epidemiología , Adolescente , Adulto , Animales , Antialérgicos/uso terapéutico , Asma/tratamiento farmacológico , Asma/etiología , Asma/terapia , Pruebas de Provocación Bronquial , Niño , Terapia Combinada , Comorbilidad , Desensibilización Inmunológica , Progresión de la Enfermedad , Hipersensibilidad a las Drogas/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Infecciones/epidemiología , Italia/epidemiología , Masculino , Cloruro de Metacolina , Persona de Mediana Edad , Pruebas de Función Respiratoria , Hipersensibilidad Respiratoria/tratamiento farmacológico , Hipersensibilidad Respiratoria/etiología , Hipersensibilidad Respiratoria/terapia , Rinitis Alérgica Perenne/tratamiento farmacológico , Rinitis Alérgica Perenne/etiología , Rinitis Alérgica Perenne/terapia , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: Some aspects of sublingual immunotherapy (SLIT) still need to be addressed: magnitude of the clinical efficacy, effect on the bronchial hyperreactivity adherence to treatment, preventive effect. We attempted to clarify these points in a randomized open, controlled, two parallel group study in a real-life setting. METHODS: Five hundred and eleven patients with allergic rhinitis with or without intermittent asthma were randomized to drugs only or drugs + SLIT (rate 2 : 3) for 3 years. The clinical score (symptoms + drug intake) was measured each year during the allergen exposure. Pulmonary function test, methacholine challenge and skin tests were performed at the beginning and at the end of the study. Adherence to treatment was assessed by measuring the consumed extract. RESULTS: Three hundred and nineteen patients received SLIT and 192 drugs only. Dropouts were 15% in the SLIT group and 12% in the controls. There was a significant improvement of clinical scores in the SLIT group: baseline 147 +/- 3.3, first year 72.9 +/- 1.3, second year 68.3 +/- 1.8, third year 54.7 +/- 2.8 (P < 0.0001 vs baseline). CONTROL GROUP: baseline 138 +/- 2.3, first year 124.1 +/- 3.7, second year 111 +/- 3.3, third year 121 +/- 3.8 (P = NS). Only four patients reported systemic itching. Adherence was >80% in 72% and >60% in 18% of patients. The number of patients with a positive MCh challenge decreased significantly after 3 years only in the SLIT group. New skin sensitizations appeared in 38% of the controls and in 5.9% of the SLIT patients (P = 0.01). CONCLUSION: Sublingual immunotherapy approximately halved the clinical scores and significantly reduced the bronchial hyperreactivity. Similarly to subcutaneous immunotherapy, SLIT displayed a preventive effect on the onset of new skin sensitizations. The adherence rate was quantitatively satisfactory.
Asunto(s)
Alérgenos/administración & dosificación , Desensibilización Inmunológica/métodos , Hipersensibilidad Respiratoria/tratamiento farmacológico , Administración Sublingual , Adolescente , Adulto , Alérgenos/inmunología , Asma/tratamiento farmacológico , Asma/inmunología , Asma/prevención & control , Hiperreactividad Bronquial/tratamiento farmacológico , Hiperreactividad Bronquial/inmunología , Hiperreactividad Bronquial/prevención & control , Niño , Preescolar , Femenino , Humanos , Inmunoterapia/métodos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Hipersensibilidad Respiratoria/inmunología , Hipersensibilidad Respiratoria/prevención & control , Rinitis/tratamiento farmacológico , Rinitis/inmunología , Rinitis/prevención & control , Resultado del TratamientoRESUMEN
Background: non-injective routes of immunotherapy in respiratory allergy have being proposed as an alternative to conventional immunotherapy. We carried out a study to evaluate the clinical efficacy and effects sublingual immunotherapy (SLIT) in patient with Cupressaceae pollen respiratory allergy. Methods: twenty patients with Cupressaceae pollen (C. sempervirens) rhinoconjunctivitis, mild asthma or both were randomly chosen for sublingual immunotherapy (10 patients) or placebo treatment (10 patients) using a double blind placebo controlled technique. We have used an extract of Cupressus arizonica because of its better stability in solution and its crossreactivity with Cupressus sempervirens. The patients underwent treatment for 12 months (from april 1999 to april 2000). Symptoms and drug scores as well as nasal provocation tests were recorded. The pollen counts were carried out, during all the same period. Results: we found significantly lower symptom scores (p < 0.05) and drug consumption scores (p < 0.05) in the immunotherapy group than in the placebo group, during the pollen season, after the first year of therapy. Besides threshold of allergen reactivity in nasal provocation tests was increased in the active group (p < 0.01). No untoward reactions have been observed. Conclusions: SLIT with Cupressus arizonica (pollen extracts) produced, after one year treatment, a significant improvement of allergic symptoms and a decrease of drug consumption scores and allergen-specific nasal reactivity. SLIT with Cupressus arizonica appeared to be effective and safe in the treatment of Cupressaceae pollen respiratory allergy (AU)
Antecedentes: en alergia respiratoria se han propuesto vías no parenterales para la inmunoterapia como alternativa a la inmunoterapia convencional.Llevamos a cabo un estudio para evaluar la eficacia clínica y los efectos de la inmunoterapia sublingual (ITSL) en pacientes con alergia respiratoria debida al polen por Cupressaceae. Métodos: se eligió aleatoriamente a 20 pacientes con alergia al polen de Cupressus sempervirens, asociada a rinoconjuntivitis, asma leve o ambas, a inmunoterapia por vía sublingual (10 pacientes) o a placebo (10 pacientes) utilizando una técnica doble ciego, controlada con placebo. Hemos utilizado un extracto de Cupressus arizonica debido a su mejor estabilidad en solución y a su reactividad cruzada con Cupressus sempervirens. Los pacientes siguieron el tratamiento durante 12 meses desde abril de 1999 a abril de 2000. Se registraron las puntuaciones de síntomas y de consumo de fármacos al igual que los resultados de las pruebas de provocación nasal. Durante el mismo período se llevaron a cabo recuentos de polen.Resultados: identificamos una puntuación significativamente menor de síntomas (p < 0,05) y de consumo de fármacos (p < 0,05) en el grupo que recibió inmunoterapia que en el grupo tratado con placebo, durante la estación del polen, después del primer año de tratamiento. Además, el umbral de reactividad al alergeno en las pruebas de provocación nasal aumentó en el grupo de tratamiento activo (p < 0,01).No se observaron reacciones adversas.Conclusiones: después de un año de tratamiento, la ITSL con extractos de polen de Cupressus arizonica produjo una mejoría significativa de los síntomas de alergia y una disminución de las puntuaciones de consumo de fármacos y de la reactividad nasal específica de alergeno. La ITSL con Cupressus arizonica parece ser eficaz y segura en el tratamiento de la alergia respiratoria debida al polen de Cupressaceae (AU)
Asunto(s)
Persona de Mediana Edad , Adulto , Adolescente , Masculino , Femenino , Humanos , Desensibilización Inmunológica , Especificidad de la Especie , Seguridad , Resultado del Tratamiento , Polen , Cupressaceae , Cupressus , Asma , Método Doble Ciego , Reacciones Cruzadas , Administración Sublingual , Alérgenos , Inmunoglobulina E , Pruebas de Provocación Nasal , Prueba de Radioalergoadsorción , Rinitis Alérgica EstacionalRESUMEN
BACKGROUND: non-injective routes of immunotherapy in respiratory allergy have being proposed as an alternative to conventional immunotherapy. We carried out a study to evaluate the clinical efficacy and effects sublingual immunotherapy (SLIT) in patient with Cupressaceae pollen respiratory allergy. METHODS: twenty patients with Cupressaceae pollen (C. sempervirens) rhinoconjunctivitis, mild asthma or both were randomly chosen for sublingual immunotherapy (10 patients) or placebo treatment (10 patients) using a double blind placebo controlled technique. We have used an extract of Cupressus arizonica because of its better stability in solution and its crossreactivity with Cupressus sempervirens. The patients underwent treatment for 12 months (from april 1999 to april 2000). Symptoms and drug scores as well as nasal provocation tests were recorded. The pollen counts were carried out, during all the same period. RESULTS: we found significantly lower symptom scores (p < 0.05) and drug consumption scores (p < 0.05) in the immunotherapy group than in the placebo group, during the pollen season, after the first year of therapy. Besides threshold of allergen reactivity in nasal provocation tests was increased in the active group (p < 0.01). No untoward reactions have been observed. CONCLUSIONS: SLIT with Cupressus arizonica (pollen extracts) produced, after one year treatment, a significant improvement of allergic symptoms and a decrease of drug consumption scores and allergen-specific nasal reactivity. SLIT with Cupressus arizonica appeared to be effective and safe in the treatment of Cupressaceae pollen respiratory allergy.